Cerus (CERS) AI Stock Analysis

• Market Cap: $338.07M
• Dividend Yield: N/A
• Average Volume (3M): 1.22M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.80
• Revenue Growth: 13.03%
• EPS Growth: 21.28%
• Country: US
• Employees: 614
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.00
• Shares Outstanding: 192,087,500
• 10 Day Avg. Volume: 1,185,582
• 30 Day Avg. Volume: 1,221,935
• PEG Ratio: 0.29
• Price to Book (P/B): 5.06
• Price to Sales (P/S): 1.58
• P/FCF Ratio: 33.35
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 1.63
• Enterprise Value/Gross Profit: 2.96
• Enterprise Value/Ebitda: -55.42
• 1Y Price Target: $4.50
• Price Target Upside: 176.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 4
• EPS Forecast (FY): -0.08
• Revenue Forecast (FY): $231.03M

• Rating: 48 Neutral
• Price Target: $1.50 ▼(-7.98% Downside)

Cerus Corporation's stock score is primarily impacted by financial instability and valuation concerns, despite positive technical indicators. The company's high leverage and ongoing losses pose significant risks, while the technical analysis suggests some positive momentum. The earnings call provided an optimistic outlook, but it is not factored into the score due to weight redistribution.

Positive Factors

Revenue Growth

The 15% YoY revenue growth indicates strong market demand and successful product adoption, supporting long-term business expansion.

International Expansion

Partnerships like the one with the German Red Cross enhance Cerus's international presence, potentially increasing market share and revenue.

Positive EBITDA

Consistent positive EBITDA reflects operational efficiency and financial health, supporting sustainable growth and investment capacity.

Negative Factors

High Leverage

High leverage can increase financial risk, limit flexibility, and strain cash flow, potentially impacting long-term stability.

Profitability Challenges

Negative profitability indicates ongoing struggles to convert revenue into profit, which could hinder growth and investor confidence.

Regulatory Delays

Regulatory delays can slow product rollout and revenue growth, affecting market competitiveness and strategic timelines.

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation (CERS) is a biomedical company focused on blood safety and the development of innovative therapies for transfusion medicine. The company operates primarily in the healthcare sector, specializing in pathogen reduction technologies for blood components. Its core product is the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections in plasma, platelets, and red blood cells. Cerus aims to enhance the safety and availability of blood products through its advanced technology.

How the Company Makes Money

Cerus generates revenue primarily through the sale of its INTERCEPT Blood System and related products to blood banks, hospitals, and healthcare providers. The company earns income from direct sales of its systems and consumables, which are used in the pathogen reduction process. Additionally, Cerus may receive revenue from licensing agreements and collaborations with other companies in the healthcare sector. Significant partnerships with blood centers and regulatory approvals enhance its market presence and contribute to consistent earnings. The company also focuses on expanding its product offerings and market reach, which plays a crucial role in driving its revenue growth.

Cerus Financial Statement Overview

Summary

Cerus shows modest revenue growth but faces significant profitability and cash flow challenges. High leverage and negative returns on equity indicate financial instability. Despite stable gross profit margins, the overall financial health is concerning due to persistent losses and cash flow issues.

Income Statement

Cerus has shown a modest revenue growth rate of 3.47% in the TTM, indicating some positive momentum. However, the company continues to face profitability challenges with a negative net profit margin of -9.81% and negative EBIT and EBITDA margins. The gross profit margin is relatively stable at 56.09%, suggesting efficient cost management at the gross level, but overall profitability remains a concern.

Balance Sheet

The company's debt-to-equity ratio is high at 1.78, indicating significant leverage, which could pose financial risks. Return on equity is negative, reflecting ongoing losses. The equity ratio is not explicitly calculated, but the high leverage suggests a lower proportion of equity in the capital structure. Overall, the balance sheet reflects financial instability and potential risk due to high debt levels.

Cash Flow

Cerus's cash flow situation is challenging, with a significant decline in free cash flow growth by -95.09% in the TTM. The operating cash flow to net income ratio is low at 0.07, indicating limited cash generation from operations relative to net income. The free cash flow to net income ratio is better at 0.60, but overall cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	199.19M	180.27M	156.37M	162.05M	130.86M	91.92M
Gross Profit	109.92M	99.52M	86.40M	87.09M	67.38M	50.76M
EBITDA	-5.87M	-10.02M	-26.34M	-33.52M	-45.99M	-51.37M
Net Income	-15.96M	-20.92M	-37.49M	-42.78M	-54.37M	-59.86M
Balance Sheet
Total Assets	215.19M	200.92M	197.75M	218.09M	237.50M	221.41M
Cash, Cash Equivalents and Short-Term Investments	78.51M	80.45M	65.85M	102.15M	129.36M	133.59M
Total Debt	98.19M	98.10M	96.00M	87.24M	87.59M	66.89M
Total Liabilities	152.98M	144.02M	144.30M	149.53M	151.88M	117.61M
Stockholders Equity	61.46M	56.15M	52.65M	67.61M	84.62M	103.81M
Cash Flow
Free Cash Flow	168.00K	8.52M	-47.77M	-27.61M	-34.83M	-43.43M
Operating Cash Flow	3.57M	11.36M	-43.17M	-25.61M	-33.92M	-41.81M
Investing Cash Flow	-12.07M	-8.13M	8.62M	8.46M	12.69M	-49.56M
Financing Cash Flow	2.01M	4.96M	10.67M	4.19M	34.29M	91.78M

Cerus Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Positive. The current price of 1.63 is above the 20-day moving average (MA) of 1.59, above the 50-day MA of 1.56, and above the 200-day MA of 1.43, indicating a bullish trend. The MACD of 0.05 indicates Negative momentum. The RSI at 62.18 is Neutral, neither overbought nor oversold. The STOCH value of 94.62 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CERS.

Cerus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	77 Outperform	$313.08M	52.43	11.05%	―	27.37%	269.84%
VMD	76 Outperform	$262.70M	20.90	10.53%	―	18.90%	29.22%
TCMD	75 Outperform	$574.25M	33.19	8.80%	―	9.28%	21.00%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CERS	48 Neutral	$338.07M	―	-27.77%	―	13.03%	21.28%
MASS	45 Neutral	$229.83M	―	-42.72%	―	4.49%	3.61%
OM	42 Neutral	$82.68M	―	-92.33%	―	4.65%	68.71%

Cerus Corporate Events

Cerus Corporation’s Q3 2025 Earnings: Growth Amid Challenges

Cerus Corporation’s recent earnings call for the third quarter of 2025 painted a picture of robust growth and optimism despite some challenges. The company reported significant revenue growth, driven by strong demand for its INTERCEPT products and successful international expansion efforts. While there are hurdles such as gross margin pressures and regulatory delays in Europe, the overall sentiment remains positive, with raised revenue guidance and a continued focus on operational execution.

Cerus Corporation Reports Record Q3 2025 Earnings

Cerus Corporation, a leader in blood safety technology, focuses on developing pathogen-protected blood components to ensure a safe global blood supply. In its latest earnings report, Cerus Corporation announced a record-breaking third quarter for 2025, with total revenue increasing by 19% to $60.2 million and product revenue reaching $52.7 million, marking a 15% year-over-year growth. The company also raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million. Key drivers of this growth include increased demand for the INTERCEPT Blood System and the INTERCEPT Fibrinogen Complex (IFC) in the U.S., with IFC sales up by 110% compared to the previous year. Cerus also completed enrollment in the U.S. RedeS trial, a pivotal Phase 3 clinical trial for its INTERCEPT Blood System for Red Blood Cells, with results expected in 2026. Financially, Cerus reported a near breakeven GAAP net loss of $0.02 million for the third quarter and a positive non-GAAP adjusted EBITDA of $5.0 million. The company remains optimistic about achieving positive full-year 2025 non-GAAP adjusted EBITDA and continues to focus on expanding its market presence and product offerings.

Cerus Corporation’s New Study on Trauma Hemorrhage Treatment: A Potential Game Changer?

The study titled Comparative Effectiveness of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (INTERCEPT Fibrinogen Complex, IFC) and Cryoprecipitate-AHF (Cryo-AHF) for Treatment of Trauma Associated Hemorrhage: CRYO-FIRST, A Quality Improvement Study aims to assess the feasibility and effectiveness of early administration of IFC in patients with hemorrhagic shock and functional hypofibrinogenemia. This study seeks to determine if advancements in rapid testing and a shelf-stable fibrinogen complex can improve the speed and effectiveness of fibrinogen replacement in trauma care.

Cerus Corporation’s New Study on Pathogen-Reduced RBCs: A Potential Game-Changer for Sickle Cell Disease

Study Overview: Cerus Corporation is conducting a study titled Kinetics of Pathogen Reduced Red Blood Cell Clearance in Subjects Undergoing Red Cell Exchange for Sickle Cell Disease. The study aims to evaluate the recovery and survival of pathogen-reduced red blood cells (RBCs) in patients with sickle cell disease (SCD) undergoing red cell exchange therapy. This research is significant as it could enhance the understanding of RBC clearance kinetics, potentially improving treatment outcomes for SCD patients.

Cerus Corporation’s New Study on INTERCEPT RBCs: Potential Market Impact

Study Overview: Cerus Corporation is conducting an open-label, controlled Phase 2 study titled Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs. The study aims to assess whether transfusing INTERCEPT RBCs into patients with pre-existing antibodies will increase antibody titers, indicating a secondary immune response, and whether these responses are linked to adverse events, increased RBC clearance, or hemolysis. The study also seeks to evaluate the recovery and survival of INTERCEPT RBCs in patients with various diseases.